Pfizer's CTI Requests Proposals for Biotherapeutic Targets

Click here for a printable PDF

Pfizer's Centers for Therapeutic Innovation, or CTI, is a unique program that collaborates with leading academic medical centers, the NIH, and foundations to speed the translation of novel targets to the clinic.

Advantages to Collaborating with CTI

A partnership with CTI may include collaborative use of Pfizer's technologies, publishing rights, and financial awards in the form of milestone and royalty payments for successful programs, in addition to providing appropriate funds for carrying out the collaborative work.

Foundations collaborating with CTI include:

• Alliance for Lupus Research
• Alzheimer's Drug Discovery Foundation
• Crohn's and Colitis Foundation of America
• Foundation for Sarcoidosis Research
• Juvenile Diabetes Research Foundation
• Jeffrey Modell Foundation

What We Look For

• Strong Project Rationale: Demonstrated association between target biology and disease mechanism
• Ability to Address Unmet Medical Needs
• Link between target pathway and human disease
• Feasibility: tractable target, discovery/development plan
• Novel drug targets with potential to lead to differentiated drugs

Modalities

Large Molecules: antibodies, proteins, peptides, ADCs, fusion proteins

Therapeutic Areas of Interest for Winter 2016

• Oncology: Immuno-oncology, epigenetic targets, novel tumor specific cell surface antigens, and targets identified by unique insights in tumor biology
• Inflammation and Immune disorders: Crohn's and Colitis, Gastrointestinal disorders, and Rheumatoid Arthritis
• Cardiovascular and metabolic diseases: NAFLD/NASH and heart failure
• Neuroscience: neurodegenerative disorders with a primary focus on Alzheimer's Disease and Parkinson's Disease (non A beta therapies) and psychiatric symptom domains such as Cognition, Anxiety, and Motivation/Apathy
• Rare monogenic genetic diseases: Hematologic, neuromuscular, pulmonary, and inherited metabolic/endocrine diseases

Pre-Proposal Submission Process

Submission entails a brief, non-confidential 2-3 page overview of the target, mechanism (including evidence for disease linkage), and the proposed therapeutic drug. At a high-level, the pre-proposal should suggest how the therapeutic hypothesis could be tested in the clinic.

All researchers and clinicians whose work meets these criteria are invited to apply.

For more information or questions, please contact Venkat Reddy at Pfizer or Nate Hafer at UMass Chan.

Thank you for your interest in Pfizer's Centers for Therapeutic Innovation.  We look forward to your ideas.